Andrew Bomback

Oct 9, 2024 | maharlikanews.com | Andrew Bomback

If you've ever laid awake at night worrying about whether you were unkind as your soul left your body when your kid rolled over 45 minutes past bedtime and asked you his 27th rapid-fire question in a row ("Why is pee hot?" followed swiftly by No. 28: "When will you die? No, like how many years exactly?").

Oct 9, 2024 | cbc.ca | Andrew Bomback |Natalie Stechyson

If you've ever laid awake at night worrying about whether you were unkind as your soul left your body when your kid rolled over 45 minutes past bedtime and asked you his 27th rapid-fire question in a row ("Why is pee hot?" followed swiftly by No. 28: "When will you die? No, like how many years exactly?").

May 22, 2024 | lupus.bmj.com | Anca D. Askanase |Richard A. Furie |Maria Dall'Era |Andrew Bomback

Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Apr 18, 2024 | medscape.com | Andrew Bomback

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published.

Mar 30, 2023 | futuremedicine.com | Andrew Bomback

Future Rare DiseasesAhead of PrintPlain Language Summary of PublicationOpen AccessAbstractWhat is this summary about? This is a summary of the article describing the design of the APPEAR-C3G clinical study, which was published in Kidney International Reports in August 2022. The APPEAR-C3G study is an ongoing study that includes participants with complement 3 glomerulopathy, known as C3G. Results of the study will be published in the future.